In a subgroup analysis of patients with acral melanoma by PD-L1 status (PD-L1 positive, n = 19; PD-L1 negative, n = 16; PD-L1 unknown, n = 3), ORR was 26.3% (95% CI, 9.1–51.2; 0 CR/5 PR) in patients with PD-L1–positive disease, 12.5% (95% CI, 1.6–38.3; 0 CR/2 PR) in patients with PD-L1–negative disease, and 0% in the 3 patients with unknown PD-L1 status (Table 3). Here, CD274 is linked to acral lentiginous melanoma.